Motivation: Many experts worldwide have highlighted the potential of RNA molecules as drug targets for the chemotherapeutic treatment of a range of diseases. In particular, the molecular pockets of RNA in the HIV-1 packaging region have been postulated as promising sites for antiviral action. The discovery of simpler methods to accurately represent drug-RNA interactions could therefore become an interesting and rapid way to generate models that are complementary to docking-based systems. Results: The entropies of a vibrational Markov chain have been introduced here as physically meaningful descriptors for the local drug-nucleic acid complexes. A study of the interaction of the antibiotic Paromomycin with the packaging region of the RNA present in type-1 HIV has been carried out as an illustrative example of this approach. A linear discriminant function gave rise to excellent discrimination among 80.13% of interacting/non-interacting sites. More specifically, the model classified 36/45 nucleotides (80.0%) that interacted with paromomycin and, in addition, 85/106 (80.2%) footprinted (non-interacting) sites from the RNA viral sequence were recognized. The model showed a high Matthews' regression coefficient (C = 0.64). The Jackknife method was also used to assess the stability and predictability of the model by leaving out adenines, C, G, or U. Matthews' coefficients and overall accuracies for these approaches were between 0.55 and 0.68 and 75.8 and 82.7, respectively. On the other hand, a linear regression model predicted the local binding affinity constants between a specific nucleotide and the aforementioned antibiotic (R 2 = 0.83, Q 2 = 0.825). These kinds of models may
INTRODUCTION
The number of new genomes has dramatically increased in recent years and this has once again highlighted the problem of protein and nucleic acid functions (Benson et al., 2000; Sakharkar et al., 2000a,b; Saxonov et al., 2000; Schisler and Palmer, 2000; Yuan, 1999) . In this respect, the use of footprint techniques has proven to be an important experimental method for the discovery of significant processes in molecular biology and the field of genomics (Tullius, 1989; Brenowitz et al., 1986; Henn et al., 2001; Galas and Schmithz, 1978; Ozoline et al., 2001; Ozoline and Tsyaganov, 1995) .
The study of drug interactions with biomolecules is a very important area of research and constitutes a significant step towards rational drug design. In this respect, modern Bioinformatics has emerged as a promising alternative and/or complement to existing experimental techniques. For example, the interactions of antibiotics (aminoglycosides) with the packaging region of HIV Type-1 appear to represent a possible new mechanism for antiviral discovery (Sullivan et al., 2002) . Aminoglycoside drugs are cationic natural products that interact with RNA (Gale et al., 1981) . These compounds act by blocking protein synthesis (Coffin, 1984; Lynch et al., 2000) and their structures can be chemically modified. In fact, aminoglycoside analogues can be used to treat certain diseases. For example, the genetic information in human immunodeficiency virus and various tumour viruses is in the form of RNA (Wilson and Li, 2000) . Since the genomes of these viruses are likely to have unique structures, it may be possible to design agents that selectively block virus proliferation by targeting a specific site on RNA (Frishman and Argos, 1997) .
Docking molecular mechanics approaches have been amongst the most widely used techniques to study host-guest molecular recognition. However, increasingly modern Bioinformatics methods (that do not involve docking techniques) have been utilized to provide structural information on Biomolecules as well as their integration with drugs (Österberg et al., 2002) . In particular, Markov models are well-known tools for analysing biological sequence data and they have been used to find new genes from the open reading frames (Vorodovsky et al., 1994 (Vorodovsky et al., , 1995 , data based searching, multiple sequence alignment of protein families and protein domains (Krogh et al., 1994) , protein α-turn types (Chou, 1997) , subcellular locations (Yuan, 1999) , for predicting secondary structures (Hubbard and Park, 1995) and protein folding recognition (Di Francesco et al., 1999) .
Our research group has recently introduced the Markovian Chemicals Drug Design (MARCH-INSIDE) approach, which has been successfully applied to fluckicidal drugs design, chirality codification and protein structure/property relationships (Gonzalez et al., 2002a,b,c) . The main objectives of the work described here were focused on deriving quantitative structure/property relationships to predict the probability (and the affinity) of drugs binding with the packaging HIV Type-1 region. MARCH-INSIDE molecular descriptors were redefined as nucleic acid backbone Markovian Vibrational Negentropies (MVN) in order to account for the structures of RNA-drug complexes.
METHODS

Modelling vibrational delocalization throughout the nucleic acid backbone
In this work the MARCH-INSIDE methodology was generalized for the study of nucleic acid-drug complexes. This approach used Markov's chain (MCH) (Gonzalez et al., 2002a,b,c; Van Kampen, 1981; Bharucha-Reid, 1960; Freund and Poschel, 2000) to codify information about molecular structure. The model considers a free drug molecule that it is in the vicinity of the RNA molecule at an arbitrary initial time (t 0 ) and interacts with some specific nucleotides of the RNA at a subsequent time (t 1 ). In order to characterize this model a number of important approximations must be taken into account. Firstly, we must accept the hypothesis that an elastic interaction governs drug-RNA binding (Landau and Lifshitz, 1963) . Secondly, the energy of this interaction will dissipate with time throughout the RNA backbone with probabilities that obey Chapman-Kolgomorov equations; consequently, k = ( 1 ) k , where k are stochastic matrices that describe the probabilities with which energy dissipates after a time t k and 1 is the same kind of matrix for the specific case t k = 1, when interaction begins (Grimmett and Stirzaker, 1992) .
Accordingly, a stochastic matrix ( 1 , with elements p ij ) could be defined. This matrix was called the 1-step vibrational-transition stochastic matrix. 1 was built as a squared table of order n, where n represented the number of nucleotides in the RNA molecule. The elements of 1 ( 1 p ij ) were defined to codify information about the strength (energy) of the drug-nucleotide interaction. Thus, when the drug molecule interacts with a specific nucleotide j of the RNA chain, the energy or 'strength' of the interaction may be described by a harmonic oscillator (Landau and Lifshitz, 1963) . Also, this energy may be carried by a wave that 'vanishes' along the polynucleotide chain with absolute probabilities A p k (j ) at discrete time periods t k = 0, 1, 2 . . . , ∞. Subsequently, both the strength of the local interaction and the topology of the RNA (secondary structure) were codified in the present scheme [see equation (1) and Fig. 1 ]. The elements ( 1 p ij ) of 1 are the transition probabilities if the nucleotides i and j are adjacent and are 0 otherwise:
For the sake of simplicity, the interaction (nucleotide-drug) was considered harmonic with energy h × υ j (h is Planck's constant), where υ j is the harmonic frequency of vibration of the local complex between the nucleotide j and the drug. Thence, k j −drug is the force constant of the link between the drug and the nucleotide j and M k−drug is the reduced mass of this complex (m j × m drug /m j + m drug ). Another simplification was to consider k j −drug as being proportional to the number of hydrogen bonding interactions H b j and the number of electrostatic interactions (1 accounts for this specific interaction) between the drug and the nucleotide. The parameter H b j equals the number of possible hydrogen bonds of each nucleotide, for nucleotides not hydrogen bonded to other nucleotides of the RNA chain. Conversely, H b j = 0 otherwise. To see more in detail the definition and calculation of the elements of the 1 matrix the study of a real example (nucleotide G292) is depicted in Table 1 .
The Markovian vibrational entropies
The extended MARCH-INSIDE RNA-drug complex molecular descriptors: (j − drug ± 3) were defined as the entropies with which the energy of the drug-nucleotide interaction 
Secondary structure of an RNA fragment of the SL 2 motif (see Fig. 2 ). c
Mathematical expression of the 1 p ij element of 1 When i = G292 and j = A293.
SL 2 292 297 285
matrix of the HIV-1 RNA packaging region as a hole contains too many (more than 300) nucleotides to be represented here (see Fig. 2 ). b,c The nucleotides in the i ± 3 vicinity of G292 are underlined, note that this set includes nucleotides that the vibration reach by first time at t k = 3, after an initial interaction of the drug with G292, including both covalent (U295, G294,A293, and U291, G290, G289) or hydrogen bonds (U288, C289) for wave transmission.
vanished in the ±3-vicinity of the nucleotide along the time (t k ):
The ±3-vicinity of the nucleotide j is a nucleotide sequence that contains the nucleotides at positions j − 3, j − 2, j − 1, j , j + 1, j + 2, j + 3 (see Fig. 1 ). The number 3 was selected as a reasonable but a priori topological distance at which the energy of the local interaction dissipates. Thereafter, the symbol k (j ± 3) was reduced to k for the sake of simplicity. These molecular descriptors for RNA-drug complexes can be interpreted as the entropy involved in the movement of the wave that carries the vibrational energy due to the interaction of the drug with the nucleotide j in the ±3-vicinity of this nucleotide after time t k .
The calculation of the absolute probabilities was straightforward on the basis of classical results from Markov chains theory (Bharucha-Reid, 1960) .
where A k represent 1 × n vectors whose elements A p k (j ) are the aforementioned absolute probabilities, A 0 represents a 1 × n vector whose elements are the A p 0 (j ) probabilities for the n atoms in the molecule and k were the kth natural powers of the 1 matrix. The A p k (j ) values were defined in a similar way to the k p ij probabilities [equation (1)] but, in this case, in the sum of all the nucleotides in the RNA molecule; see González et al. for an exhaustive explanation ( Gonzalez et al., 2002a,b,c) . All of the calculations were performed using our experimental software MARCH-INSIDE (Hernández and González, 2002) . For any information about this programme please e-mail the corresponding author humbertogd@navegalia.com.
The data set of footprinted and binding nucleotides was extracted from the literature (McPike et al., 2002) . The secondary structure of the HIV Type-1 -RNA packaging region as well as the binding sites of Paromomycin are depicted in Figure 2 .
Computer software implementation status
The calculation of k for short to middle length RNA secondary structures (having 2 to around 600 nucleotides) was implemented in an updated experimental version of our software MARCH-INSIDE. This software has a graphical interface that makes it user friendly. The chemical structure is drawn directly using the molecular graphics in the software draw mode. Clicking in an upper dynamic array, which contains icons representing the one letter symbol of the nucleotides, changes the nucleotide selected to draw. It is afterwards possible to select the calculation option and perform the calculation of molecular indices. RNA sequences very much larger than 600 are yet not possible to manage.
RESULTS
MVN and the probability of footprinting after RNA-paromomycin interaction
Linear Discriminant Analysis (LDA; Manhnhold et al., 1995; Statsoft Inc., 2002) was used to classify nucleotides as footprinted or not footprinted after exposure of RNA to the drug. In the development of the LDA the output was a dummy variable: Binding, which codify the presence (Binding = 1) or absence (Binding = 0) of structural changes for each specific nucleotide on the presence of RNAses (without specifying the RNAse type). In this problem the input where the k , with k in the range [0, 10] Matthews' regression coefficient (C) quantified the strength of the linear relation between the molecular descriptors and the drug-nucleotide interaction classifications (Hua and Sun, 2001; Matthews, 1975) . The coefficient ρ was used to control the ratio of the adjustable parameters in the model with respect to the number of variables (Garcia-Domenech et al., 1998) . A high degree of collinearity was detected between k and so the dependent variables were orthogonalized according to Randič's orthogonalization procedure (Randič, 1993) , mean-centered (with the arithmetic mean) and scaled with 1/sd(xi) 2 , the inverse of the squared standard deviation (Myers, 1997; Geladi and Kowalski, 1986; Martens and Naes, 1989) . Here, we used the symbols I O( k ), where the superscript I expresses the order of importance of the variable ( k ) after a preliminary forward stepwise analysis and O means orthogonal. Jackknife experiments were performed by leaving out all the nucleotides with a common base and deriving the model under the same conditions. All of the statistical parameters of the new models obtained after removing the nucleotides were checked in order to assess the stability of the model. Matthews' coefficients and the overall accuracies for those models were: C A = 0.64 (82.7%), C C = 0.68 (80%), C G = 0.55 (75.8%) and C U = 0.61 (78.8%).
MVN modeling of Paromomycin's affinity constant with HIV Type 1 -RNA
A model such as that represented by equation (4) may be very useful to predict the probability of an interaction occurring between the drug and a specific site of the RNA chain. However, any picture of the drug-RNA interaction would be incomplete without some knowledge of the strength of each interaction. For this reason a quantitative linear model was developed in order to predict the magnitude of the interactions. where N is the number of interactions with a known affinity constant (K), log K was the output of the model, F is Fisher's statistics, Std.Err. is the standard error of estimates, R 2 is the squared regression coefficient for training and Q 2 the same for the leave-one-out procedure. One special input for this model was the dummy variable RNAse, which has the values RNAse = 1 for experiments carried out in the presence of RNAse I and RNAse = −1 for RNAse T1. Additionally, the k , with k in the range [0, 10] , were used as well. The results for the residuals analysis are depicted in Table 2 .
DISCUSSION
In the first instance, the statistical significance of the results must be discussed before arriving at any conclusions concerning the biology involved. As shown in the results section, the p-level of Fisher's test for the LDA was <0.05. This means that the hypothesis of groups overlapping with a 5% error can be rejected. Additionally, a high C value (0.64) indicates a strong linear relation between molecular descriptors and the classification of nucleotides. This value, as well as the overall accuracy, remained stable in Jackknife procedures, a fact that indicates an acceptable level of predictability (Myers, 1997; Geladi and Kowalski, 1986) . In the LDA, calculating the ρ coefficient (37.7) controls the number of variables in the equation with respect to the number of cases. This coefficient must be higher than 4 for linear models (Garcia-Domenech and Ortiz, 1998). The MVNs ( k ), as defined here, make use of the Shannon concept of entropy as reported by Richard and Kier (1980) . However, these parameters were defined over a timedependent Markov chain and such a definition attempts to model the biological data using a realistic physical model.
It must be pointed out that equation (4) involves shortrange (k = 5), middle-range (5 < k < 10) and far-reaching vibrations (k = 10 or greater). This situation means that the probability of binding decreases with the MVN involved in the early stages of drug-nucleotide interaction (−0.897). Such behaviour may be explained by taking into consideration the fact that the higher the vibrational entropy changes in the nucleotide backbone, which are necessary for the drugnucleotide interaction, the more marked structural changes in the ±3-vicinity of the nucleotide. Consequently, the probability of the drug binding to the RNA decreases. Conversely, middle range vibrations seem to stabilize the nucleotidedrug complex with the probability of binding increasing by a factor of 0.658 for each kJ K −1 of entropy [see equation (4)]. In any case, interactions that generated far-reaching waves with vanishing periods higher than 10 also decreased the binding probability. These seem to be very unstable interactions between the drug and the nucleotide. The time scale in the present model (t k ) is the same as that used for the specific experiment described in the literature (McPike et al., 2002) . Footprinting techniques can now act as timeresolved methods in the millisecond scale (Henn et al., 2001) . Equation (5) was found to be statistically significant (p < 0.05). The high R 2 value meant that the model accounted for 83% of the data variability. The relatively few cases reported for log K(10 −4 M −1 ) led us to perform a Jackknife procedure to assess the stability and predictability of the model. The squared cross-validation regression coefficient showed that the model is capable of explaining the same variance as in training (83/82.5%).
Equation (5) involves the use of either middle-range or longrange vibrational waves. It is remarkable that the parameters that appear in equation (4) are virtually identical to those used in equation (5) and also have proportional contributions. In general, it was shown here that the generalized vibrational MARCH-INSIDE model can codify useful chemical information that accounts for drug-RNA interactions. In this way, the model could be of great help in studying the mechanism of action of antiviral drugs that are designed to act against HIV using their packaging region as a target. The models described here may be generalized to other RNAdrug systems by changing both the RNA structure and the reduced mass of the nucleotide-drug pairs. The approach described here represents a novel and very promising way to design antiviral drugs (Hermann and Westhof, 2000) . However, a more in-depth discussion is beyond the scope of the present work.
